Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

• Status: RECRUITING
• Trial end date: 2026-09-03

Summary

A phase III multi-center randomized, double-blind and positive-controlled clinical trial for evaluating the efficacy and safety of BCG for Therapeutic Use（BCG） in the prevention of postoperative recurrence of medium/high-risk non-muscle invasive bladder cancer (NMIBC).

• Phase: PHASE3

Details

• Lead Sponsor: Chengdu CoenBiotech Co., Ltd
• Collaborator: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Treatments: Therapeutic Uses